253
views
0
recommends
+1 Recommend
0 collections
    4
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Options on fibroid morcellation: a literature review

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In laparoscopy, specimens have to be removed from the abdominal cavity. If the trocar opening or the vaginal outlet is insufficient to pass the specimen, the specimen needs to be reduced. The power morcellator is an instrument with a fast rotating cylindrical knife which aims to divide the tissue into smaller pieces or fragments. The Food and Drug Administration (FDA) issued a press release in April 2014 that discouraged the use of these power morcellators. This article has the objective to review the literature related to complications by power morcellation of uterine fibroids in laparoscopy and offer recommendations to laparoscopic surgeons in gynaecology. This project was initiated by the executive board of the European Society of Gynaecological Endoscopy. A steering committee on fibroid morcellation was installed and experienced ESGE members requested to chair an action group to address distinct clinical questions. Clinical questions were formulated with regards to the sarcoma risk in presumed uterine fibroids, diagnosis of sarcoma, complications of morcellation and future research. A literature review on the different subjects was conducted, systematic if appropriate and feasible. It was concluded that the true prevalence of uterine sarcoma in presumed fibroids is not known given the wide range of prevalences (0.45–0.014 %) from meta-analyses mainly based on retrospective trials. Age and certain imaging characteristics such as ‘lacunes’ suggesting necrosis and increased central vascularisation of the tumour are associated with a higher risk of uterine sarcoma, although the risks remain low. There is not enough evidence to estimate this risk in individual patients. Complications of morcellation are rare. Reported are direct morcellation injuries to vessels and bowel, the development of so-called parasitic fibroids requiring reintervention and the spread of sarcoma cells in the abdominal cavity, which may possibly or even likely upstaging the disease. Momentarily in-bag morcellation is investigated as it may possibly prevent morcellation complications. Because of lack of evidence, this literature review cannot give strong recommendations but offers only options which are condensed in a flow chart. Prospective data collection may clarify the issue on sarcoma risk in presumed fibroids and technology to extract tissue laparoscopically from the abdominal cavity should be perfected.

          Related collections

          Most cited references92

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical management of uterine sarcomas.

          Malignant pure mesenchymal uterine tumours encompass endometrial stromal sarcoma (ESS), uterine leiomyosarcoma, and undifferentiated sarcomas. This Review discusses pathology, preoperative diagnosis, and standard treatment of uterine leiomyosarcoma and low-grade ESS (distinct from undifferentiated uterine sarcomas), with an emphasis on targeted treatment. We show that several features on ultrasonography and MRI can raise suspicion of a uterine sarcoma; however, there are no pathognomonic features on any imaging technique. For both ESS and uterine leiomyosarcoma, hysterectomy with bilateral salpingo-oophorectomy, but without lymphadenectomy, is the standard surgical treatment for early stage disease. The clinical benefit of chemotherapy is limited, which underscores the importance of targeted therapy. ESS and uterine leiomyosarcoma are driven by different pathways, resulting in a different clinical behaviour. ESS typically is a hormone-sensitive tumour with indolent growth. Uterine leiomyosarcoma is notorious for its aggressive growth and poor outcome. Individualisation of treatment is mandatory, because randomised trials are almost non-existent. The progesterone and oestrogen receptors are clinically important targets for most primarily advanced or recurrent ESS and a subset of recurrent uterine leiomyosarcomas. Potential future targets and targeted treatments that are under investigation are presented for both entities.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Uterine myomas: an overview of development, clinical features, and management.

            To review the biology and the pathophysiology of uterine myomas, focus on options for management, and emphasize principles that will render the decision-making process as logical as possible. Literature review and synthesis of the authors' experience and philosophy. Uterine myomas are the most common solid pelvic tumors in women. There is increasing evidence that they have a genetic basis and that their growth is related to genetic predisposition, hormonal influences, and various growth factors. Treatment choices are wide and include pharmacologic, surgical, and radiographically directed intervention. Most myomas can be followed serially with surveillance for development of symptoms or progressive growth. The past century has witnessed development of highly sophisticated diagnostic and therapeutic technology for myomas. The tools currently at our disposal permit greater management flexibility with safe options, which must be tailored to the individual clinical situation.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases.

              A recent trend in the classification of uterine smooth muscle neoplasms (USMNs) into clinically benign and clinically malignant groups has been to move from exclusive reliance upon mitotic index (MI) to an approach that incorporates additional histopathologic characteristics. In furtherance of this goal, we assessed a variety of histopathologic features of 213 problematic smooth muscle neoplasms for which we had > or = 2 years of clinical follow-up data or for which there was an unfavorable outcome. One hundred and thirteen of these patients have had a minimum follow-up of 5 years, and 48 have been followed for > or = 10 years. Cases eliminated from the study group included USMNs with a significant myxoid or epithelioid component and cases of intravenous leiomyomatosis. USMNs, whether cellular or not, with no cytologic atypia and with a mitotic index (MI = number of mitotic figures [mf]/10 high-power fields [hpf]) of or = 10 mf/10 hpf, four of 10 failed.(ABSTRACT TRUNCATED AT 400 WORDS)
                Bookmark

                Author and article information

                Contributors
                +31 20 4442227 , h.brolmann@vumc.nl
                v.tanos@aretaeio.com
                Journal
                Gynecol Surg
                Gynecol Surg
                Gynecological Surgery
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                1613-2076
                1613-2084
                7 February 2015
                7 February 2015
                2015
                : 12
                : 1
                : 3-15
                Affiliations
                [ ]Department of Gynaecology, VU University Medical Centre, de Boelelaan 1117, 1181HV Amsterdam, The Netherlands
                [ ]Department of Obstetrics and Gynaecology, Aretaeio Hospital, St George’s Medical School, Nicosia University, Nicosia, Cyprus
                [ ]Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Thessaloniki, Greece
                [ ]Department of Gynaecological Oncology, Royal Marsden Hospital, London, UK
                [ ]Spire Hull and East Riding Hospital, London, UK
                [ ]Catholic University Leuven, Leuven, Belgium
                [ ]Donauisar Klinikum Deggendorf-Dingolfing-Landau, Deggendorf, Germany
                [ ]Leiden University Medical Centre, Leiden, The Netherlands
                [ ]Elisabeth-twee steden Hospital, Tilburg, The Netherlands
                [ ]Department for Women’s Health, University Hospital Tuebingen, Eberhard Karls University, Tübingen, Germany
                [ ]IRCAD, Strassburg, France
                [ ]Leuven Institute for Fertility and Embryology (LIFE), Leuven, Belgium
                [ ]M.E.R.I.T. Centre, Bradford Royal Infirmary, Bristol, UK
                [ ]Pius Hospital, Oldenburg, Germany
                Article
                878
                10.1007/s10397-015-0878-4
                4349949
                25774118
                a4cb0b79-eafe-426c-a667-dea2ad400d6f
                © The Author(s) 2015

                Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

                History
                : 8 December 2014
                : 1 January 2015
                Categories
                Review Article
                Custom metadata
                © Springer-Verlag Berlin Heidelberg 2015

                Obstetrics & Gynecology
                leiomyoma uteri,leiomyosarcoma,endometrial stromal sarcoma,laparoscopy,morcellation,power morcellation,complication

                Comments

                Comment on this article

                scite_

                Similar content368

                Cited by26

                Most referenced authors775